Subtitle: Market Intelligence, Selective Calcineurin Inhibition Strategies, Clinical Progress, and High-Purity Reagents for Immunomodulation & Neurological Disease Development.
Key Molecular Features of PPP3R1
PPP3R1 (Calcineurin B, CNB1) is the regulatory subunit of the Calcineurin holoenzyme. It contains three EF-hand domains (EF-hand 1, 2, and 3; UniProt P63098) that bind calcium and induce conformational changes required for catalytic activation of PPP3CA. The EF-hand motifs are critical for calcium-dependent phosphatase activity and represent key targets for allosteric inhibition. High-purity recombinant proteins with wild-type or EF-hand mutant sequences are essential for mechanistic studies.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PPP3R1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PPP3R1 Wild-Type & EF-Hand Mutant Proteins. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Calcium-binding verified by structural analysis. | View PPP3R1 Products |
| Complex Protein | PPP3R1/PPP3CA Heterodimer. Pre-formed calcineurin holoenzyme complex. Theoretical MW verified. Activity-ready format for direct use in phosphatase assays. | View PPP3R1 Products |
| Gene Delivery | PPP3R1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. Suitable for overexpression studies in HEK293. | View PPP3R1 Products |
| Validator | PPP3R1 siRNA Set. For knockdown verification and specificity controls in cellular assays. | View PPP3R1 Products |
| Benchmark Ab | Anti-PPP3R1 recombinant positive control for assay validation (Western blot, ELISA). | View PPP3R1 Products |
| Catalytic Partner | PPP3CA (Calcineurin A). Catalytic subunit for holoenzyme reconstitution and phosphatase assays. | View PPP3CA Products |
| Downstream Target | NFATC1 (Nuclear Factor of Activated T-Cells). Transcription factor substrate for functional readout assays. | View NFATC1 Products |
| Related Target | FKBP1A (FKBP12). Immunophilin that forms a ternary complex with FK506 and Calcineurin to block NFAT signaling. | View FKBP1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-dependent conformational changes | EF-hand mutant panel (E→A mutations) available with >95% purity for mechanistic studies |
| Phosphatase activity quantification | PPP3R1/PPP3CA pre-complexed proteins with validated theoretical specific activity parameters |
| Isoform selectivity (PPP3R1 vs PPP3R2) | Human PPP3R1 and PPP3R2 ortholog proteins with sequence-verified specificity |
| Cellular validation | Sequence-verified siRNA sets for knockdown confirmation and target engagement verification |
| Complex Formation Validation | High-purity (>95%) monomers and heterodimer configurations available for reliable SPR and PPI assays |
| Lack of Reliable Controls | Sequence-verified benchmark antibodies for reproducible Western blotting and ELISA |
Live PPP3R1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Selective Inhibitor Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The calcineurin inhibitor market is undergoing a paradigm shift from broad immunosuppression (Cyclosporine A, Tacrolimus) to selective PPP3R1/PPP3CA disruption. While legacy therapies broadly target the calcinuerin complex, modern therapeutics are shifting towards highly selective protein degraders (PROTACs), allosteric inhibitors, and peptide inhibitors targeting the subunit interface. Next-generation drug development focuses on peptide inhibitors targeting the interface between regulatory and catalytic subunits, as well as PROTAC approaches for selective degradation. The R&D focus is on isolating neurological and cardiac benefits without inducing nephrotoxicity or broad immunosuppression. As first-generation calcineurin inhibitors face toxicity limitations (nephrotoxicity, neurotoxicity), the industry is prioritizing isoform-selective modulators that preserve immunosuppressive efficacy while reducing side effect profiles.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Inhibitors | Academic consortia, Biotech ventures, Spin-offs | Autoimmune diseases, Transplant rejection, Cardiac hypertrophy | PPP3R1/PPP3CA dimerization assays (Need high-purity complex proteins) |
| Small Molecule (Selective) | Novartis, Astellas, Takeda | Psoriasis, Rheumatoid arthritis, Organ rejection | Calcium-binding competition assays (Need EF-hand mutants), Selectivity Assay (Need High-Purity Calcineurin A/B complexes) |
| PROTAC/Degraders | Emerging biotech | Neurodegeneration, Cardiac hypertrophy | Cellular target engagement (Need ORF lentivirus for stable lines), Ternary complex validation (Need native conformation proteins) |
| Gene Therapy (siRNA) | Alnylam pipeline analogs | Localized immunosuppression | Knockdown validation (Need validated siRNA controls) |
Related Targets for Cross-Selling
- PPP3CA (Calcineurin A) – Catalytic subunit; forms obligatory heterodimer with PPP3R1. Essential for phosphatase activity assays and holoenzyme reconstitution.
- NFATC1 – Direct downstream substrate; key readout for functional assays (NFAT reporter cell lines, dephosphorylation assays).
- FKBP1A (FKBP12) – Intracellular receptor for Tacrolimus; mediates ternary complex formation with calcineurin for immunosuppression studies.
- RCAN1 (Regulator of Calcineurin 1) – Endogenous inhibitor; competes with PPP3R1 for binding to PPP3CA; relevant for disease mechanism studies (e.g., Down syndrome).